Screener
Theravance Biopharma TBPH Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Receivables from collaborative arrangements | 15,584 | 45,539 |
| Receivables from milestones and royalty assets | — | 50,000 |
| Other prepaid and current assets | 7,384 | 7,564 |
| Total current assets | 417,634 | 418,460 |
| Long-term marketable securities | — | 11,128 |
| Property and equipment, net | 5,539 | 5,895 |
| Operating lease assets | 23,001 | 24,371 |
| Restricted cash | 836 | 836 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's total current assets?
- Theravance Biopharma (TBPH) reported total current assets of $417.63M in Q1 2026.
- How has Theravance Biopharma's total current assets changed year-over-year?
- Theravance Biopharma's total current assets increased by 177.9% year-over-year, from $150.26M to $417.63M.
- What is the long-term trend for Theravance Biopharma's total current assets?
- Over 5 years (2020 to 2025), Theravance Biopharma's total current assets has grown at a 1.2% compound annual growth rate (CAGR), from $393.34M to $418.46M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Theravance Biopharma's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude